Eton Pharmaceuticals Inc (NASDAQ:ETON)’s traded shares stood at 0.34 million during the last session, with the company’s beta value hitting 1.38. At the close of trading, the stock’s price was $14.41, to imply an increase of 0.91% or $0.13 in intraday trading. The ETON share’s 52-week high remains $15.00, putting it -4.09% down since that peak but still an impressive 78.97% since price per share fell to its 52-week low of $3.03. The company has a valuation of $383.80M, with an average of 0.32 million shares in intraday trading volume over the past 10 days and average of 228.37K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Eton Pharmaceuticals Inc (ETON), translating to a mean rating of 1.00. Of 1 analyst(s) looking at the stock, 0 analyst(s) give ETON a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 1 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.0.
Eton Pharmaceuticals Inc (NASDAQ:ETON) trade information
After registering a 0.91% upside in the last session, Eton Pharmaceuticals Inc (ETON) has traded red over the past five days. The 5-day price performance for the stock is 7.22%, and 13.11% over 30 days. With these gigs, the year-to-date price performance is 8.18%. Short interest in Eton Pharmaceuticals Inc (NASDAQ:ETON) saw shorts transact 0.19 million shares and set a 0.93 days time to cover.
The extremes give us $11 and $15 for target low and target high price respectively. As such, ETON has been trading -4.09% off suggested target high and 23.66% from its likely low.
Eton Pharmaceuticals Inc (ETON) estimates and forecasts
Looking at statistics comparing Eton Pharmaceuticals Inc share performance against respective industry, we note that the company has underperformed competitors. Eton Pharmaceuticals Inc (ETON) shares are 321.34% up over the last 6 months, with its year-to-date growth rate lower than industry average at -250.00% against 16.60%. The rating firms project that company’s revenue will grow 19.87% compared to the previous financial year.
Revenue forecast for the current quarter as set by 3 analysts is 10.55M. Meanwhile, for the current quarter, a total of 2 analyst(s) estimate revenue growth to 12.91M.Earnings reports from the last fiscal year show that sales brought in 7.31M and 7.97M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 44.33% before jumping 62.02% in the following quarter.
ETON Dividends
Eton Pharmaceuticals Inc has its next earnings report out in February. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Eton Pharmaceuticals Inc (NASDAQ:ETON)’s Major holders
Eton Pharmaceuticals Inc insiders hold 5.39% of total outstanding shares, with institutional holders owning 33.36% of the shares at 35.26% float percentage. In total, 33.36% institutions holds shares in the company, led by OPALEYE MANAGEMENT INC.. As of 2024-06-30, the company held over 2.4 million shares (or 9.2963% of shares), all amounting to roughly $7.88 million.
The next major institution holding the largest number of shares is VANGUARD GROUP INC with 1.03 million shares, or about 3.989% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $3.38 million.
We also have Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund as the top two Mutual Funds with the largest holdings of the Eton Pharmaceuticals Inc (ETON) shares. Going by data provided on Sep 30, 2024 , Vanguard Total Stock Market Index Fund holds roughly 681.72 shares. This is just over 2.62% of the total shares, with a market valuation of $9.82 million. Data from the same date shows that the other fund manager holds a little less at 307.58, or 1.18% of the shares, all valued at about 4.43 million.
